المؤلفون: Cassius, Charles, Pages, Cécile, Roux, Jennifer, Lhote, Raphael, Lavocat, Romain, Réa, Delphine, Bagot, Martine, Mourah, Samia, Battistella, Maxime, Lebbé, Céleste, Dumaz, Nicolas

المصدر: Journal of Investigative Dermatology ; volume 136, issue 6, page 1302-1305 ; ISSN 0022-202X

مصطلحات موضوعية: Cell Biology, Dermatology, Molecular Biology, Biochemistry

الإتاحة: https://doi.org/10.1016/j.jid.2015.12.047Test
https://api.elsevier.com/content/article/PII:S0022202X16004590?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0022202X16004590?httpAccept=text/plainTest

المؤلفون: Hurabielle, Charlotte, Pillebout, Evangéline, Stehlé, Thomas, Pagès, Cécile, Roux, Jennifer, Schneider, Pierre, Chevret, Sylvie, Chaffaut, Cendrine, Boutten, Anne, Mourah, Samia, Basset-Seguin, Nicole, Vidal-Petiot, Emmanuelle, Lebbé, Céleste, Flamant, Martin

المصدر: PLoS ONE; 3/1/2016, Vol. 11 Issue 3, p1-8, 8p

مصطلحات موضوعية: CREATININE, BLOOD plasma, BRAF genes, MELANOMA treatment, DRUG side effects, DISEASE prevalence, RETROSPECTIVE studies, ACQUISITION of data

مستخلص: Context: Serum creatinine has been reported to increase in patients receiving Vemurafenib, yet neither the prevalence nor the mechanism of this adverse event are known. Objective: We aimed to evaluate the frequency and the mechanisms of increases in plasma creatinine level in patients receiving Vemurafenib for advanced melanoma. Methods: We performed a retrospective monocentric study including consecutive patients treated with Vemurafenib for an advanced melanoma. We collected clinical and biological data concerning renal function before introduction of Vemurafenib and in the course of monthly follow-up visits from March 2013 to December 2014. Cystatin C-derived glomerular filtration rate was evaluated before and after Vemurafenib initiation, as increase in serum cystatin C is specific to a decrease in the glomerular filtration rate. We also performed thorough renal explorations in 3 patients, with measurement of tubular secretion of creatinine before and after Vemurafenib initiation and a renal biopsy in 2 patients. Results: 70 patients were included: 97% of them displayed an immediate, and thereafter stable, increase in creatinine (+22.8%) after Vemurafenib initiation. In 44/52 patients in whom Vemurafenib was discontinued, creatinine levels returned to baseline. Serum cystatin C increased, although proportionally less than serum creatinine, showing that creatinine increase under vemurafenib was indeed partly due to a renal function impairment. In addition, renal explorations demonstrated that Vemurafenib induced an inhibition of creatinine tubular secretion. Conclusion: Thus, Vemurafenib induces a dual mechanism of increase in plasma creatinine with both an inhibition of creatinine tubular secretion and slight renal function impairment. However, this side effect is mostly reversible when Vemurafenib is discontinued, and should not lead physicians to discontinue the treatment if it is effective. [ABSTRACT FROM AUTHOR]

: Copyright of PLoS ONE is the property of Public Library of Science and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)